百奧賽圖-B(02315.HK)RenMab技術平臺再獲日本專利授權，持續深化RenMice全人抗體╱TCR平臺全球專利佈局
格隆匯6月5日丨百奧賽圖-B(02315.HK)宣佈，其自主研發的全人抗體小鼠RenMab®平臺關鍵技術獲得由日本專利局(Japan Patent Office, JPO)頒發的發明專利證書。這是百奧賽圖RenMice®全人抗體平臺家族在全球知識產權保護的又一關鍵進展，標誌着其系統性全球專利佈局戰略的穩步推進與深化，充分彰顯了其核心技術的創新性與國際認可度。
RenMab®小鼠是百奧賽圖自主研發的RenMice®全人抗體發現平臺家族的核心成員之一。百奧賽圖利用獨有的超大片段染色體工程技術(SUPCE®)，將小鼠的抗體重鏈和輕鏈可變區基因原位全區段替換爲人的相應基因。由此RenMab小鼠具有完整的人抗體重鏈VDJ基因和輕鏈VJ基因，和野生鼠一樣，RenMab小鼠能針對不同的抗原均產生強免疫應答，能夠產生最大程度保留天然多樣性的全人抗體分子，顯着提高發現高潛力抗體藥物分子的成功率。RenMab小鼠產生的全人抗體分子無需進行復雜的抗體人源化改造，有效降低了抗體藥物開發過程中的免疫原性風險，大幅提高了研發效率和成功率。
RenMice®系列小鼠平臺(包括RenMab®、RenLite®、RenNano®、RenTCR-mimic®和RenTCR™)在發現低免疫原性、高多樣性、高親和力及理化性質優良的全人抗體╱TCR方面的卓越優勢，已獲得全球頂尖製藥企業和生物技術公司的廣泛認可。百奧賽圖已與包括德國默克、楊森╱強生、百濟神州等在內的約20家國內外領先企業達成了RenMice平臺授權合作。基於RenMice平臺的「千鼠萬抗」工程，針對上千潛在藥物靶點產生上百萬條全人抗體分子，以及高潛力臨牀前候選抗體分子，截至2024年底百奧賽圖已達成近200個抗體分子的授權╱轉讓合作，充分證明瞭RenMice平臺的國際競爭力和商業價值。
憑藉持續的自主研發和底層技術創新能力，百奧賽圖持續在全球範圍內積極進行RenMice®平臺專利佈局和關鍵技術保護。截止目前，RenMice平臺已在美國、中國、日本等近10個國家獲得專利授權，並在15個國家和地區將近40項專利申請推進到審查階段，未來有望陸續獲得更多專利授權。百奧賽圖全球專利佈局戰略的穩步推進，將持續爲全球合作夥伴提供堅實的知識產權保障。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
